Table 1.
Demographic and clinical characteristics of the whole cohort of patients
| Patients, n | 19 |
| AQP4-IgG, n (%) | 12 (63.16) |
| MOG-IgG, n (%) | 3 (15.79) |
| Double-negative, n (%) | 4 (21.05) |
| Age, years (SD) | 52.74 (17.60) |
| Female, n (%) | 16 (84.20%) |
| Disease duration, years (SD) | 12.13 (5.84) |
| EDSS pre-RTX start, (range) | 2.0 (0–7.5) |
| EDSS after RTX start (range) | 2.5 (0–7.5) |
| ARR 1 year before RTX start (SD) | 2.37 (1.34) |
| ARR after RTX start (SD) | 0.08 (0.11) |
| Relapse free time, years (SD) | 7.92 (4.35) |
| Previous treatments, n (range) | 1 (0–4) |
| Previous immunosuppressive treatment history, n (%) | 11 (57.89) |
| Naive | 8 |
| Azathioprine | 7 |
| Prednisone | 3 |
| Interferon beta-1a | 3 |
| Methotrexate | 2 |
| Mychophenolate mofetil | 2 |
| Cyclophosphamide | 1 |
| Mitoxantrone | 1 |
| Follow-up time from RTX start, years (range) | 7.64 (3.09–16.25) |